CanSino Biologics partners with deepGeneAI to develop personalized mRNA cancer vaccines
PUBT · 1d ago
Share
Listen to the news
- CanSino Biologics unit CanSino Shanghai signed a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA cancer vaccines.
- Collaboration targets tumor neoantigen discovery and design paired with CanSino’s mRNA vaccine technology.
- Work sits within CanSino’s early-stage mRNA platform push into therapeutic vaccines and related delivery systems.
- Announcement dated Aug. 26, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300293), on August 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending